Medunik Canada and Lucane Pharma Conclude an Exclusive Licence and Collaboration Agreement to Help Canadian Patients Suffering From Urea Cycle Disorders (UCD), a Group of Rare Inherited Diseases

Medunik Canada and Lucane PharmaMedunik Canada and Lucane Pharma Conclude an Exclusive Licence and Collaboration Agreement to Help Canadian Patients Suffering From Urea Cycle Disorders (UCD), a Group of Rare Inherited DiseasesInherited Diseases PR Newswire BLAINVILLE, Quebec, December 4, 2013 Medunik Canada, a pharmaceutical company specialized in orphan drugs and Lucane Pharma, a French niche pharmaceutical company, announced the conclusion of an exclusive collaboration agreement. Through this agreement, Medunik Canada receives the exclusive Canadian rights to market and distribute a new therapeutic option for patients suffering from Urea Cycle Disorders (UCD), a group of rare diseases involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate sythetase. This therapeutic option is taste-free, which facilitates medication and favours compliance to treatment. "We are very happy about this alliance with Lucane Pharma," stated Éric Gervais, Executive Vice-President of Medunik Canada. "This new collaboration complements our existing alliances, making Medunik Canada the largest orphan drug company in Canada. It also reinforces our position as a strategic partner committed to help Canadian rare disease patients benefit from the best available treatments." "We are confident in Medunik Canada's ability and enthusiasm to make this new treatment option available to Canadian patients with DCU ", said Pierre Mambrini, CEO of Lucane Pharma.